Publication: Pathogenic PSEN1 Glu184Gly mutation in a family from Thailand with probable autosomal dominant early onset Alzheimer’s disease
1
Issued Date
2020-02-01
Resource Type
ISSN
20754418
Other identifier(s)
2-s2.0-85081384075
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diagnostics. Vol.10, No.3 (2020)
Suggested Citation
Vorapun Senanarong, Seong Soo A. An, Vo van Giau, Chanin Limwongse, Eva Bagyinszky, Sang Yun Kim Pathogenic PSEN1 Glu184Gly mutation in a family from Thailand with probable autosomal dominant early onset Alzheimer’s disease. Diagnostics. Vol.10, No.3 (2020). doi:10.3390/diagnostics10030135 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/53589
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pathogenic PSEN1 Glu184Gly mutation in a family from Thailand with probable autosomal dominant early onset Alzheimer’s disease
Abstract
© 2020 by the authors. A pathogenic mutation in PSEN1 p.Glu184Gly was discovered in a Thai family with early onset Alzheimer’s disease (EOAD) as the first case in Asia. Proband patient presented memory impairment and anxiety at the age of 41 years. Family history was positive, since several family members were also diagnosed with dementia (father and grandfather). MRI in the patient revealed global cortical atrophy without specific lesions or lacuna infarctions. Extensive genetic profiling for 50 neurodegenerative disease related genes was performed by next generation sequencing (NGS) on the patient. PSEN1 Glu184Gly was previously reported in French families with frontal variant Alzheimer’s disease (AD). Interestingly, this mutation is located near the splicing site and could possibly result in abnormal cleavage of PSEN1 transcript. Furthermore, 3D models from protein structural predictions revealed significant structural changes, since glycine may result in increased flexibility of TM-III helix. Inter/intra-helical interactions could also be altered. In the future, functional studies should be performed to verify the probable role PSEN1 Glu184Gly in amyloid beta processing and pathogenicity.